News

AG Mednet Strengthens Leadership with New Executive Hires

AG Mednet Strengthens Leadership with New Executive Hires

AG Mednet Expands Leadership to Power Judi’s Next Phase of Growth

AG Mednet, known for clinical trial process management, is experiencing strong momentum as its Judi platform gains broad adoption. Judi now supports more than 2,000 clinical trials and works alongside 640 drug and device sponsors and 90 Contract Research Organizations (CROs) worldwide.

Rapid Growth of the Judi Platform

Growing demand for Judi has prompted AG Mednet to deepen its leadership bench. The company has appointed Catherine Tyner as Head of Clinical Strategy and Jamie Russo as Head of Product. These hires are designed to help the team scale thoughtfully while continuing to deliver the quality, reliability, and innovation partners expect as usage of the Judi platform accelerates.

Catherine Tyner’s Mandate

Catherine Tyner brings 27 years of clinical research experience, with a focus on Oversight Group Management for Clinical Endpoint Committees and other critical operations. Her leadership career includes roles at Quintiles, Novella Clinical, and Covance. She has led oversight departments supporting more than 500 clinical trials, including complex, multi-therapeutic studies. As Head of Clinical Strategy, she will concentrate on optimizing clinical processes to increase value for both new and existing sponsors and CROs.

Tyner on Joining AG Mednet

Tyner shared her perspective: “I’m thrilled to be joining AG Mednet at such a pivotal time. The Judi platform is leading the way in clinical process management, showcasing excellence in data monitoring and adjudication best practices. I look forward to driving further progress in this space and contributing to Judi’s growth and adoption.”

Focus on Product Innovation

Appointing Jamie Russo as Head of Product underscores AG Mednet’s commitment to advancing its product strategy. Russo brings more than a decade of experience spanning healthcare and technology, including roles at PathAI and Massachusetts General Hospital. Her work centers on aligning healthcare technology with the practical, evolving needs of clinical research teams.

Russo’s Vision

In her new role, Russo plans to expand AI-enabled capabilities across the Judi platform. She recognizes AG Mednet’s record of helping clinical trials run efficiently and sees a clear path for future growth. “I’m eager to help propel the innovation that has defined AG Mednet,” she said.

A Commitment to Quality and Precision

AG Mednet’s CEO, Abraham Gutman, emphasized that the company will continue to meet rising demand for Judi with a focus on quality and precision. The leadership updates reflect AG Mednet’s dedication to consistent, incremental innovation across the clinical development lifecycle.

Embedding Efficiency in Clinical Trials

As Judi evolves, AG Mednet is strengthening collaboration among sponsors, CROs, and oversight groups. The company’s focus remains on improving the efficiency of event adjudication, eligibility determination, and remote monitoring so study teams can move faster while maintaining rigor.

Global Impact of the Judi Platform

Adoption of Judi has driven broader collaboration across the industry. Over the past year alone, AG Mednet added more than 100 unique trial sponsors. The platform now supports studies across 20 therapeutic areas, demonstrating its adaptability to many trial designs and operational needs.

Future Directions for AG Mednet

Looking ahead, AG Mednet plans to carry this momentum into the new year. The focus remains on advancing clinical research with innovative AI solutions and on building collaborations that help bring therapies to patients more efficiently worldwide.

About AG Mednet

AG Mednet streamlines the clinical trial process with its award-winning Judi platform, which simplifies essential workflows, improves communication, and helps accelerate the development of life-saving therapies. With broad adoption among global biopharmaceutical sponsors and leading CROs, Judi supports transparency and efficiency across clinical processes, from endpoint adjudication to data safety monitoring.

Frequently Asked Questions

What is Judi, and how widely is it used?

Judi is AG Mednet’s platform for clinical trial process management. It is in use across more than 2,000 clinical trials with participation from 640 drug and device sponsors and 90 CROs, supporting activities such as event adjudication, eligibility determination, remote monitoring, and data safety monitoring.

Who are the new leaders, and what will they do?

Catherine Tyner has joined as Head of Clinical Strategy, bringing 27 years of clinical research experience and a background in oversight for Clinical Endpoint Committees. Jamie Russo is the new Head of Product, with more than ten years in healthcare and technology. Together, they will optimize clinical processes and guide the platform’s product strategy, including AI-enabled capabilities.

Why is AG Mednet expanding its leadership now?

Demand for Judi is surging. Expanding the leadership team helps AG Mednet scale responsibly, maintain high standards for quality and precision, and continue delivering innovation as more sponsors and CROs adopt the platform.

What impact is Judi having globally?

Judi has supported wide industry collaboration, including onboarding more than 100 unique trial sponsors in the past year. The platform is used across 20 therapeutic areas, reflecting its flexibility for different study designs and operational needs.

How will AI shape the next phase of Judi?

Under Jamie Russo’s product leadership, AG Mednet plans to extend AI-enabled solutions across Judi. The goal is to help clinical trials run efficiently while supporting high standards in data monitoring and adjudication—advancing the company’s ongoing commitment to innovation.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Cottage Grove Tests Holiday Demand Across Lake Norman

Updated Category News Views 125

Flour and foot traffic make a pretty honest little scoreboard. Cottage Grove Bakery is putting itself in front of Lake Norman shoppers twice on Saturday, November 21, while also taking Thanksgiving orders and laying groundwork for 2027 workplace and school visits. This is not a public-company earnings story, and nobody should pretend a tray of scones is a quarterly...

Continue Reading
PexarBolt's CES Honor Meets a Real Crowdfunding Test

Updated Category News Views 77

A little touchscreen bolted onto a dock would usually make me roll my eyes. This time, Pexar has at least put enough muscle behind the gimmick to deserve a harder look. The PexarBolt Ultra TBT5 Dock was named a CES Innovation Awards 2027 Honoree in Computer Peripherals & Accessories, following an IFA 2026 Innovation Awards honor only two months after its launch. Awards do...

Continue Reading
Tessera Delisting Leaves HLSQ in a Tougher Market Ahead

Updated Category News Views 116

November delivered a nasty little truth serum for Tessera Defense and Homeland Security: exchange status is not a cosmetic detail when the stock’s selling price has collapsed. On November 10, NYSE Regulation suspended trading in the company’s common shares on NYSE American and began delisting proceedings. By November 17, Tessera had a chance to request review by the...

Continue Reading
Six LIFE Photographers Bring History Into Florida Focus

Updated Category News Views 72

Seventy photographs can make a pretty loud argument when the historical record has been this lopsided. The Ashley Gibson Barnett Museum of Art at Florida Southern College has brought LIFE: Six Women Photographers to Lakeland, and it deserves more than the usual polite nod given to a traveling museum show. Open since November 14, 2026, and running through March 7, 2027,...

Continue Reading
Simmons Clarifies Texas Loan Exposure, But Risks Remain

Updated Category News Views 87

A $45 million discrepancy is not a rounding error, and Simmons First National has every reason to swat it down hard. The bank says recent reporting overstated financing tied to a Texas multifamily development at $133 million. Its stated total is roughly $88 million, with about $44 million participated to another financial institution. For shareholders in NASDAQ:SFNC, that...

Continue Reading
Greenberg Traurig Adds Privacy Muscle in Denver Office

Updated Category News Views 162

Privacy work used to be the legal department's back-room plumbing; now it can jam an entire product launch. That is why Greenberg Traurig's decision to bring Amber Mednick in as of counsel in Denver deserves more attention than the usual law-firm hiring blurb. This is not a splashy deal, and nobody should pretend one lateral hire rewrites the competitive map. Still, it is...

Continue Reading
Sitting, Lymph Flow, and a Supplement Maker's Pitch

Updated Category News Views 32

By late afternoon, a chair can feel like it has quietly won the argument against your legs. PureHealth Research is leaning into that familiar heavy, puffy-legged feeling with a reminder about lymphatic flow—and, naturally, an eight-ingredient supplement positioned alongside it. The broad message is sensible. The sales layer needs the usual healthy squint. Movement Does...

Continue Reading
OU's $44.3M Rural Care Plan Targets Oklahoma Care Gaps

Updated Category News Views 100

A Long Drive Is a Brutal Barrier to Care Seventy-five of Oklahoma's 77 counties sit in health professional shortage territory, a figure that ought to stop people cold. It means at least 3,500 patients per provider in those counties. That is not some abstract planning headache. It is the pregnant patient delaying a specialist visit, the family weighing an ambulance ride,...

Continue Reading
Faex Health Adds Ebola and H. pylori AI Screening Tools

Updated Category News Views 82

A smartphone pointed at a toilet is an awkward place to hunt for medical progress, yet Faex Health is making a serious attempt to turn that daily evidence into an early-warning tool. The company has added investigational pre-screening capabilities for Ebola virus disease and Helicobacter pylori, or H. pylori, bringing its internally validated panel to 18 gastrointestinal...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 40

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading

Top 5 Most Recently Viewed Articles

Significant Unusual Options Activity Signals Opportunity in GOOGL

Updated Category News Views 97

Analyzing Recent Options Activity for Alphabet Currently, investors are exhibiting a strong bullish sentiment towards Alphabet (NASDAQ: GOOGL), a trend that is capturing the attention of market participants. Recent observations of public options have revealed significant movements in GOOGL, hinting at potential changes ahead. Recent analyses have uncovered 129 unusual...

Continue Reading
Encore and UKG Introduce Innovative Overtime Savings Program

Updated Category News Views 298

Encore and UKG Join Forces for Employee Financial Wellness Encore, a prominent global leader in event technology and production services, has unveiled an innovative ‘Overtime Savings Program’ in collaboration with UKG, a top provider of HR and workforce management solutions. This remarkable initiative aims to empower Encore's frontline workers, allowing them to save...

Continue Reading
Discover Incredible Returns from Texas Pacific Land Investments

Updated Category News Views 160

The Incredible Growth of Texas Pacific Land Corp Texas Pacific Land Corp (NYSE: TPL) has marked its presence in the market with an outstanding performance over the past 15 years. The company has outshone the market median by an impressive 32.71% annually, which translates to a staggering average annual return of 45.46%. With a current market capitalization nearing $20.51...

Continue Reading
Cypherpunk Q2 2026: Zcash Growth Sparks Market Buzz

Updated Category News Views 76

Cypherpunk Technologies' Stellar Q2 Performance Sit tight, folks, because Cypherpunk Technologies just unleashed a financial update that's got the market buzzing. They've reported a staggering net income of $39.4 million for Q2 2026, quite the turnaround from a $16.6 million loss in the same quarter last year. It's a serious win, no doubt pumped up by their fruitful Zcash...

Continue Reading
Exciting Findings from Aicuris’ Clinical Trials of AIC468

Updated Category News Views 182

Encouraging Insights into AIC468 from Clinical Trials Recently, a notable advancement in medical research has emerged from Aicuris Anti-infective Cures AG regarding its novel treatment, AIC468. This drug is an innovative antisense oligonucleotide targeting the BK virus, particularly in kidney transplant recipients. The first-in-human (FIH) Phase 1 trial has provided...

Continue Reading